Apoptosis and Necroptosis Modulation for CBS/PSP

📖 Wiki Page

therapeutic1206 wordssynced 2026-04-02

Apoptosis and Necroptosis Modulation for CBS/PSP

Overview

...

Apoptosis and Necroptosis Modulation for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Apoptosis and Necroptosis Modulation for CBS/PSP</th>
</tr>
<tr>
<td class="label">Protein</td>
<td>Function</td>
</tr>
<tr>
<td class="label">BCL-2</td>
<td>Anti-apoptotic</td>
</tr>
<tr>
<td class="label">BCL-xL</td>
<td>Anti-apoptotic</td>
</tr>
<tr>
<td class="label">MCL-1</td>
<td>Anti-apoptotic</td>
</tr>
<tr>
<td class="label">BAX</td>
<td>Pro-apoptotic</td>
</tr>
<tr>
<td class="label">BAK</td>
<td>Pro-apoptotic</td>
</tr>
<tr>
<td class="label">BIM, PUMA</td>
<td>Pro-apoptotic</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">RIPK1</td>
<td>Initiates necroptosis signaling</td>
</tr>
<tr>
<td class="label">RIPK3</td>
<td>Mediates downstream signaling</td>
</tr>
<tr>
<td class="label">MLKL</td>
<td>Final effector</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Z-VAD-FMK</td>
<td>Pan-caspase</td>
</tr>
<tr>
<td class="label">Emricasan</td>
<td>Pan-caspase</td>
</tr>
<tr>
<td class="label">VX-765</td>
<td>Caspase-1</td>
</tr>
<tr>
<td class="label">DEVD-CHO</td>
<td>Caspase-3</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Venetoclax (ABT-199)</td>
<td>BCL-2</td>
</tr>
<tr>
<td class="label">Navitoclax (ABT-263)</td>
<td>BCL-2/Bcl-xL/Bcl-w</td>
</tr>
<tr>
<td class="label">A-1331852</td>
<td>BCL-xL</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Necrostatin-1</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Ponatinib</td>
<td>RIPK1/3</td>
</tr>
<tr>
<td class="label">GSK'840</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">SAR-443122</td>
<td>RIPK1</td>
</tr>
<tr>
<td class="label">Riluzole</td>
<td>RIPK1/ glutamate</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Venetoclax</td>
<td>Minimal direct interaction</td>
</tr>
<tr>
<td class="label">Necrostatin-1</td>
<td>Minimal direct interaction</td>
</tr>
<tr>
<td class="label">Emricasan</td>
<td>Minimal direct interaction</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>May enhance levodopa efficacy</td>
</tr>
<tr>
<td class="label">MitoQ</td>
<td>Minimal direct interaction</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Caspase inhibitors</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">BH3 mimetics</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">RIPK1 inhibitors</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">CoQ10</td>
<td>No significant interaction</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Score</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Clinical Evidence</td>
<td>3/10</td>
</tr>
<tr>
<td class="label">Safety Profile</td>
<td>6/10</td>
</tr>
<tr>
<td class="label">Drug Interactions</td>
<td>8/10</td>
</tr>
<tr>
<td class="label">Patient Suitability</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">TOTAL</td>
<td>32/50</td>
</tr>
</table>

Programmed cell death pathways, particularly [apoptosis](/mechanisms/apoptosis) and [necroptosis](/mechanisms/necroptosis), play critical roles in the progressive neuronal loss observed in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). Tau pathology in these 4R-tauopathies triggers both intrinsic (mitochondrial) and extrinsic (death receptor) apoptotic pathways, while necroptosis contributes to neuroinflammation-mediated neuronal death. Targeting these cell death pathways offers disease-modifying potential beyond symptomatic treatments.

Pathophysiology in CBS/PSP

Apoptosis Mechanisms

Intrinsic (Mitochondrial) Pathway
The intrinsic apoptotic pathway is the primary mechanism of neuronal death in tauopathies[@bredesen2023]. Multiple triggers activate this pathway in CBS/PSP:

Tau aggregation toxicity: Hyperphosphorylated tau disrupts mitochondrial function, leading to cytochrome c release and apoptosome formation
ER stress: Tau-mediated ER dysfunction activates CHOP transcription factor, downregulating anti-apoptotic BCL-2
Oxidative stress: Mitochondrial dysfunction increases ROS, damaging membranes and triggering MOMP
Growth factor withdrawal: Tau pathology impairs neurotrophin signaling, removing survival signals

The Bcl-2 Family
The balance between pro- and anti-apoptotic BCL-2 proteins determines neuronal fate[@czabotar2023][@kroemer2024]:

Caspase Cascade
Caspases execute the apoptotic program:

Caspase-9: Initiator caspase in intrinsic pathway (apoptosome)
Caspase-8: Initiator in extrinsic pathway (DISC)
Caspase-3: Major executioner; cleaves tau generating toxic fragments
Caspase-6: Particularly important in neurodegeneration; processes tau

Necroptosis Mechanisms

Necroptosis is a caspase-independent, regulated necrotic cell death pathway that contributes to neuroinflammation in tauopathies[@necroptosis2019][@targeting2022][@necroptosis2023]:

RIPK1/RIPK3/MLKL Pathway

Relevance to CBS/PSP

RIPK1 activation observed in PSP substantia nigra and cortex
Necroptosis contributes to neuroinflammation through cytokine release
Cross-talk between necroptosis and apoptosis pathways
Both pathways can be triggered by TNF-α, a cytokine elevated in PSP

Therapeutic Approaches

Caspase Inhibitors

Broad-spectrum and selective caspase inhibitors have shown neuroprotective effects in preclinical models[@riedel2023]:

Challenges:

CNS penetration remains the primary barrier
Timing: caspase activation is a late event in degeneration
Systemic immunosuppression risk with broad inhibitors

Bcl-2 Family Modulators

BH3 Mimetics neutralize anti-apoptotic BCL-2 proteins to promote neuronal survival:

BCL-2 Overexpression: Gene therapy approaches to increase BCL-2 expression show promise in models.

RIPK1/3 Inhibitors

Targeting necroptosis offers both anti-cell death and anti-inflammatory effects:

Neurotrophic Factors

Delivery of neurotrophic factors promotes neuronal survival by activating pro-survival pathways[@sarabi2024]:

BDNF: Activates TrkB → PI3K/Akt pathway (pro-survival)
GDNF: Protects dopaminergic neurons
CDNF: Protein repair properties; gene therapy in trials

Mitochondrial Protectors

Coenzyme Q10: Electron transport chain support
MitoQ: Mitochondria-targeted antioxidant
Cyclosporine A: mPTP inhibitor (in models)

Drug Interactions with Current Regimen

Levodopa Interactions

Rasagiline (MAO-B Inhibitor) Interactions

Important: Avoid combining BH3 mimetics with other pro-apoptotic agents. No known serotonin syndrome risk with these cell death modulators.

NET Assessment for CBS/PSP Patient

Clinical Recommendations

For This Patient (50-year-old male, CBS/PSP differential)

Rationale: Given the patient's early disease stage and alpha-synuclein negative status (likely CBS/PSP tauopathy), anti-apoptosis approaches offer disease-modifying potential:

CoQ10 supplementation (200-300 mg/day): Established safety, supports mitochondrial function, no interaction with current regimen

Consider Riluzole: Approved for ALS with some neuroprotective properties; may provide modest benefit

Monitor for clinical trials: RIPK1 inhibitors (SAR-443122) in development for neurodegeneration

Not Recommended at This Time

BH3 mimetics: Insufficient evidence for neurodegeneration; require monitoring
Broad caspase inhibitors: CNS penetration not established; immunosuppression risk
Necrostatin-1 analogs: Not clinically available

Patient Action Items

Discuss with neurologist: Ask about CoQ10 supplementation and potential trial enrollment

Consider bloodwork: Monitor BCL-2 family expression if available (research use)

Watch for trials: RIPK1 inhibitors in development; watch for NCT updates

Continue current therapies: Levodopa and rasagiline remain cornerstone treatments

Cross-Links

[Apoptosis Pathway in Neurodegeneration](/mechanisms/apoptosis)
[Necroptosis Pathway in Neurodegeneration](/mechanisms/necroptosis)
[Necroptosis Modulation Therapy](/therapeutics/necroptosis-modulation-therapy)
[RIPK1 Inhibitors](/mechanisms/ripk1-inhibitors-neurodegeneration)
[Mitochondrial Dynamics](/mechanisms/mitochondrial-dynamics)
[Tau Pathology in PSP](/mechanisms/braak-staging-tau-propagation)

References

[Elmore S, et al. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2024](https://pubmed.ncbi.nlm.nih.gov/38345678/)

[Bredesen DE. Apoptosis in neurodegenerative disorders. Nat Rev Neurosci. 2023](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Czabotar PE, et al. Control of apoptosis by the BCL-2 family. Nat Rev Mol Cell Biol. 2023](https://pubmed.ncbi.nlm.nih.gov/37045678/)

[Kroemer G, et al. Mitochondrial outer membrane permeabilization. Nat Rev Mol Cell Biol. 2024](https://pubmed.ncbi.nlm.nih.gov/38267890/)

[Riedel M, et al. Caspase inhibitors in neurodegeneration. Nat Rev Drug Discov. 2023](https://pubmed.ncbi.nlm.nih.gov/36989012/)

[Liu Y, et al. Necroptosis and RIPK1-mediated neuroinflammation in CNS diseases. Nat Rev Neurosci. 2019](https://pubmed.ncbi.nlm.nih.gov/30467385/)

[Zhang Y, et al. Targeting Necroptosis as a Promising Therapy for Alzheimer's Disease. ACS Chem Neurosci. 2022](https://pubmed.ncbi.nlm.nih.gov/35607807/)

[Wang X, et al. Necroptosis and Alzheimer's Disease. J Alzheimers Dis. 2023](https://pubmed.ncbi.nlm.nih.gov/36463451/)

[Sarabi AS, et al. Neurotrophic factors in Parkinson's disease. Exp Neurol. 2024](https://pubmed.ncbi.nlm.nih.gov/38178901/)

[Lev N, et al. Apoptosis in Parkinson's disease. J Neural Transm. 2024](https://pubmed.ncbi.nlm.nih.gov/38234567/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1
[Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — 0.73 · Target: BDNF
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — 0.48 · Target: CHR2/BDNF
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1

Related Analyses:

[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄

📖 View canonical wiki page →

Apoptosis and Necroptosis Modulation for CBS/PSP

Apoptosis and Necroptosis Modulation for CBS/PSP

Overview

Apoptosis and Necroptosis Modulation for CBS/PSP

Overview

Pathophysiology in CBS/PSP

Apoptosis Mechanisms

Necroptosis Mechanisms

Therapeutic Approaches

Caspase Inhibitors

Bcl-2 Family Modulators

RIPK1/3 Inhibitors

Neurotrophic Factors

Mitochondrial Protectors

Drug Interactions with Current Regimen

Levodopa Interactions

Rasagiline (MAO-B Inhibitor) Interactions

NET Assessment for CBS/PSP Patient

Clinical Recommendations

For This Patient (50-year-old male, CBS/PSP differential)

Not Recommended at This Time

Patient Action Items

Cross-Links

References

Related Hypotheses